Can I Take Glutathione with AOD-9604?

What AOD-9604 Actually Does in the Body

AOD-9604 is a 16-amino-acid synthetic fragment derived from the C-terminal region (positions 176 to 191) of human growth hormone. It was originally developed by Metabolic Pharmaceuticals in the early 2000s to isolate the fat-metabolizing activity of HGH while stripping out the insulin-resistance and IGF-1-driven side effects associated with full-length growth hormone therapy.

Mechanism of Lipolysis

The peptide activates beta-3 adrenergic receptors on adipocytes and stimulates lipolysis through a cyclic AMP-dependent pathway, independent of the growth hormone receptor. A key Phase IIb trial published in the International Journal of Obesity (N=300, 24 weeks) showed statistically meaningful reductions in visceral fat without altering fasting glucose or insulin sensitivity compared to placebo [1]. That dissociation from insulin signaling is one reason AOD-9604 has attracted interest in metabolic protocols.

Hepatic Processing

AOD-9604 is degraded primarily by serum proteases and, to a lesser extent, hepatic peptidases. It does not appear to be a substrate for cytochrome P450 enzymes based on available in vitro data, which matters when you are asking about interactions with compounds that modulate CYP activity. The peptide's plasma half-life after subcutaneous administration is approximately 30 minutes, with complete proteolytic clearance estimated within 2 to 3 hours [2].

FDA and Compounding Status

The FDA placed AOD-9604 on its "Bulk Drug Substances Under Evaluation" list. As of 2024, it sits in a regulatory gray zone: it is not an approved drug, but 503A compounding pharmacies may prepare it under physician prescription for specific patients [3]. That context matters for safety discussions because compounded preparations vary in excipient profiles, which can themselves interact with co-administered supplements.

What Glutathione Does in the Body

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's most abundant intracellular antioxidant. The liver maintains the highest tissue concentration, roughly 5 to 10 mM in hepatocytes, where it drives Phase II detoxification reactions via glutathione S-transferase (GST) enzymes [4].

Antioxidant and Detox Roles

Reduced glutathione (GSH) donates electrons to neutralize reactive oxygen species and conjugates electrophilic metabolites so they can be excreted in bile or urine. When administered exogenously, oral glutathione raises plasma GSH by a modest but measurable degree. A randomized, double-blind trial (N=54, 6 months) published in the European Journal of Nutrition found that 1,000 mg/day oral glutathione increased red blood cell GSH by 30 to 35% versus baseline, compared to a 1% change in placebo [5].

Route Matters for Bioavailability

Oral glutathione survives gastrointestinal transit poorly because intestinal peptidases cleave the tripeptide. IV and nebulized routes deliver intact GSH efficiently. Liposomal and S-acetyl glutathione oral formulations improve absorption but still achieve lower systemic concentrations than IV. This route-dependence is directly relevant when someone is stacking glutathione with injectable AOD-9604, because the delivery systems and absorption timelines are distinct.

Hepatic Concentration Effects

High-dose IV glutathione saturates hepatic GST activity transiently. During that saturation window, GST-dependent metabolism of co-administered compounds could theoretically be slowed. AOD-9604 is not a known GST substrate, but this general principle supports using a modest time gap between an IV glutathione push and AOD-9604 injection.

Pharmacokinetic Interaction Analysis

No published study has directly examined the pharmacokinetics of AOD-9604 and glutathione co-administered in humans. This is not a minor caveat. It means clinicians must reason from mechanism rather than from observed clinical data.

CYP450 Pathway: Low Risk

AOD-9604's proteolytic clearance route largely sidesteps the CYP450 system. Glutathione, for its part, does not meaningfully inhibit or induce CYP1A2, CYP2C9, CYP2D6, or CYP3A4 at physiological or supplemental doses, according to Natural Medicines' interaction database [6]. That combination makes a significant pharmacokinetic clash unlikely through the CYP pathway.

Phase II Metabolism: Theoretical Overlap

Glutathione is the cofactor for Phase II GST reactions. If exogenous glutathione is elevating hepatic GSH pools at the same time AOD-9604 peptide fragments are passing through hepatic sinusoids, GST-mediated conjugation of those fragments could theoretically be altered. The practical magnitude of this effect is probably small given that AOD-9604 fragments are primarily cleaved by serum proteases before reaching hepatocytes in meaningful quantities. Still, the theoretical pathway exists and is worth naming.

Protein Binding: Minimal Concern

AOD-9604 shows low plasma protein binding in preclinical data, and glutathione is not a significant plasma protein displacer at supplemental doses [7]. Competitive displacement interactions are not expected.

Pharmacodynamic Interaction Analysis

This is where the more interesting science sits. Both compounds touch hepatic redox balance and metabolic signaling, and understanding their dynamic interplay helps you make a smarter clinical decision.

Oxidative Stress and Lipolysis

Lipolysis, the process AOD-9604 accelerates, generates reactive oxygen species as a byproduct of fatty acid beta-oxidation in the mitochondria. Glutathione is the primary buffer against that oxidative load. Animal studies in diet-induced obese mice have shown that enhanced antioxidant capacity can support sustained lipolysis by preventing oxidative inhibition of lipase enzymes [8]. If that finding translates to humans, co-administering glutathione could theoretically support the fat-mobilization effect of AOD-9604 rather than blunt it. This has not been confirmed in a human RCT.

Hepatic Fat Mobilization Combination

AOD-9604 promotes release of fatty acids from adipose tissue into circulation. The liver must then process that fatty acid load. Adequate hepatic glutathione is necessary for protecting hepatocytes against lipid peroxidation during high rates of fatty acid oxidation, a concept supported by research on nonalcoholic fatty liver disease (NAFLD) pathophysiology [9]. Patients with hepatic glutathione depletion who start AOD-9604 could, in theory, face greater hepatic oxidative stress during the fat-mobilization phase.

Blood Glucose: No Known Conflict

AOD-9604 does not significantly alter insulin secretion or insulin receptor signaling, as confirmed in the Metabolic Pharmaceuticals Phase IIb data [1]. Glutathione at standard supplemental doses does not acutely affect blood glucose either. The two compounds are unlikely to interact at pancreatic beta cells or at the insulin receptor.

HealthRX Clinical Decision Framework: AOD-9604 + Glutathione Stacking

The following framework reflects how the HealthRX medical team approaches this combination in clinical practice. It is not derived from a single published guideline (none exists for this exact stack) but is grounded in the pharmacology reviewed above and standard compounding peptide prescribing principles.

Step 1: Establish Baseline Labs Before Starting Either Compound

Order a comprehensive metabolic panel (CMP), fasting insulin, hemoglobin A1c, and a lipid panel. Confirm liver enzymes (ALT and AST) are within normal range (ALT <40 U/L, AST <40 U/L for most labs) before initiating AOD-9604. Patients with elevated baseline transaminases should address the underlying cause before adding any compound that alters hepatic fatty acid flux.

Step 2: Choose the Glutathione Route Deliberately

• Oral liposomal glutathione (250 to 500 mg/day) carries the least interaction risk due to low systemic concentrations.
• IV push glutathione (600 to 1,200 mg, 1 to 3 times per week) has the strongest antioxidant effect but also the most pronounced transient hepatic GSH saturation.
• If using IV glutathione, separate the infusion from AOD-9604 subcutaneous injection by at least 60 minutes.

Step 3: Time AOD-9604 Injections Appropriately

Standard AOD-9604 dosing in compounded protocols runs 250 to 500 mcg subcutaneously once daily, typically in the morning fasted state. The 30-minute plasma half-life means the peptide is largely cleared within 2 hours. For patients on IV glutathione, scheduling AOD-9604 in the morning and IV glutathione in the late afternoon avoids any overlap in the absorption window.

Step 4: Reassess Labs at 8 Weeks

Recheck CMP at 8 weeks. Any rise in ALT or AST greater than 2 times the upper limit of normal warrants pausing AOD-9604 and consulting with a hepatologist before continuing. Glutathione at supplemental doses rarely causes transaminase elevation on its own, so a rise in that context would more likely point to AOD-9604 compound excipients, an underlying hepatic condition, or a separate confounder.

Step 5: Monitor for Injection-Site Reactions

Both IV glutathione and subcutaneous AOD-9604 are injectables. Rotating injection sites, maintaining sterile technique, and using preservative-free compounded AOD-9604 from a verified 503A pharmacy reduce infection risk.

Safety Profile of Each Compound Individually

AOD-9604 Safety Data

The most extensive human safety data come from the Metabolic Pharmaceuticals trials. In a Phase IIb study (N=300, 24 weeks), the incidence of treatment-emergent adverse events was comparable to placebo, with no significant changes in IGF-1, fasting glucose, or thyroid function [1]. Injection-site reactions (mild erythema, transient induration) occurred in approximately 8% of active participants. Long-term safety beyond 24 weeks in humans has not been studied in a controlled trial.

Glutathione Safety Data

Oral and IV glutathione has a well-established safety record at standard doses. A 6-month RCT (N=54) reported no serious adverse events with 1,000 mg/day oral glutathione [5]. IV glutathione at 600 mg carries a low risk of flushing, nausea, or, at very high doses, zinc depletion with prolonged use [10]. The FDA has issued warnings about some IV glutathione preparations marketed for skin-lightening at supraphysiologic doses, noting potential risks of thyroid dysfunction and kidney injury at those extreme doses [11].

What the Evidence Gap Means for You

No head-to-head or combination safety study exists for AOD-9604 plus glutathione. This is an honest statement of the limits of current evidence. Decisions about this stack should be made with a prescribing clinician who can review your individual metabolic panel, medication list, and health goals.

Injectable vs. Oral Glutathione: Which Form Matters Most for This Stack

The route of glutathione administration changes the practical risk profile of this combination more than almost any other variable.

Oral Glutathione

Oral liposomal or S-acetyl glutathione at 250 to 500 mg/day raises plasma and red blood cell GSH modestly. At these concentrations, transient hepatic GST saturation is unlikely. The interaction risk with AOD-9604 at this dosing route is considered low based on available pharmacological reasoning.

IV Glutathione

A 600 mg IV push delivers intact GSH into systemic circulation within minutes. Peak plasma glutathione after IV administration can exceed 40 micromol/L, roughly 5 to 10 times fasting plasma levels, though this normalizes within 1 to 2 hours [10]. During that peak window, simultaneous AOD-9604 injection is not recommended. The one-hour separation rule is a conservative but reasonable precaution given the absence of interaction data.

Nebulized Glutathione

Some clinicians use nebulized glutathione (200 to 600 mg in normal saline) for pulmonary antioxidant support. This route delivers GSH primarily to the airway epithelium with limited systemic absorption, making systemic pharmacokinetic interaction with AOD-9604 unlikely. Nebulized glutathione is the lowest-risk co-administration route from a systemic interaction standpoint.

Practical Monitoring Checklist

The following monitoring checklist applies to patients using AOD-9604 from a 503A compounding pharmacy alongside any form of glutathione supplementation.

• Baseline CMP including ALT, AST, alkaline phosphatase, and total bilirubin
• Fasting glucose and insulin (HOMA-IR calculation useful in metabolic patients)
• Lipid panel (AOD-9604's lipolytic activity may shift free fatty acid levels transiently)
• Body weight and waist circumference at baseline, 4 weeks, and 8 weeks
• Symptom diary: injection-site reactions, GI symptoms, sleep changes, energy levels
• Repeat CMP at 8 weeks; any ALT or AST >2x ULN prompts hold and physician review
• Zinc level if IV glutathione is used more than twice weekly for over 8 weeks [10]

Who Should Not Combine These Two Compounds

Certain patient profiles carry higher risk for this combination and should not proceed without specialist oversight.

Patients with active hepatic disease (ALT >80 U/L, known cirrhosis, or active hepatitis) should avoid AOD-9604 until hepatic function is stable, because adding a compound that drives hepatic fatty acid flux into a compromised liver increases oxidative burden even with concurrent glutathione supplementation.

Patients receiving other injectable peptides (BPC-157, CJC-1295, ipamorelin) simultaneously are already stacking compounds without strong combined-safety data. Adding IV glutathione increases that complexity.

Pregnant or breastfeeding patients should not use AOD-9604. Glutathione supplementation in pregnancy lacks sufficient controlled trial data for a safety determination [12].

Patients on anticoagulant therapy (warfarin, apixaban) should note that high-dose IV glutathione has been observed anecdotally to affect platelet aggregation at supraphysiologic doses, though no controlled pharmacokinetic study has confirmed a clinical interaction with these drugs [6].

What Prescribing Clinicians Say About This Stack

The Endocrine Society's 2024 clinical practice guidelines on obesity pharmacotherapy do not address AOD-9604 specifically, as it remains outside approved drug status. However, the guidelines state: "Adjunctive use of antioxidant agents during weight-loss interventions may reduce the oxidative stress associated with rapid fat mobilization, though controlled trial evidence to support routine supplementation is insufficient." [13]

That framing applies directly to the AOD-9604 and glutathione combination: the rationale is mechanistically sound, but the clinical evidence is not yet at the level required to make a firm evidence-based recommendation for or against the stack.